Repair Biotechnologies has secured FDA Rare Disease Evidence Principles (RDEP) eligibility for REP-0003, an mRNA therapy targeting intracellular free cholesterol accumulation in homozygous familial hypercholesterolemia. This regulatory milestone enables a more tractable clinical pathway for a therapy designed to remove established atherosclerotic damage rather than simply manage lipid levels—a distinction with implications extending beyond inherited cholesterol disorders to broader cardiovascular aging.
Key Points
- REP-0003 targets intracellular cholesterol toxicity, not lipid levels alone
- RDEP eligibility accelerates clinical development in high-need rare disease
- Mechanism addresses fundamental atherosclerosis driver across multiple tissues
Longevity Analysis
The fundamental shift here is from risk management to damage removal. Medicine has long emphasized slowing atherosclerotic progression through lipid modification; this approach proposes that some existing cellular damage may be reversible. If REP-0003 demonstrates efficacy in clearing intracellular cholesterol burden—a shared pathological mechanism across liver, retina, brain, and other tissues—it establishes a proof-of-concept for repair-based geroscience in cardiovascular disease. The implication extends beyond HoFH: intracellular cholesterol accumulation appears to be a broader driver of age-related vascular decline, making this rare disease indication a potential entry point for therapies addressing foundational cellular dysfunction that accelerates aging.
Original published by Longevity.Technology, by Eleanor Garth.